EMNIFY
20.2.2024 15:01:33 CET | Business Wire | Press release
Today, emnify, the leader in cloud-native IoT connectivity solutions, announces the general availability of the industry’s first converged cellular and satellite IoT connectivity on a single emnify IoT eSIM. SuperNetwork SatPlus is offered as part of the emnify SuperNetwork, the leading IoT cellular connectivity service providing multi-network coverage in over 180 countries.
The SuperNetwork SatPlus package combines emnify’s IoT-dedicated cellular access with Skylo’s non-terrestrial network (NTN) satellite service, enabling IoT device manufacturers, OEMs and application and solution providers to add a new level of service enabled by seamless, satellite connectivity failover for devices outside of, or disconnected from, cellular coverage.
SuperNetwork SatPlus opens up a whole new level of IoT connectivity availability for use cases in asset tracking, fleet management, building safety and security, agriculture, and more. IoT businesses can now differentiate their product and service experience and drive their top line revenues by offering a premium level of data connectivity service: ubiquitous coverage even in the most remote areas.
How SuperNetwork SatPlus works
emnify IoT SuperNetwork SatPlus is available in selected European countries and the USA and includes 10MB of cellular connectivity combined with options for 10, 30 or 60 satellite messages per month. With SatPlus, SuperNetwork customers have the security of ubiquitous, uninterrupted IoT connectivity, with seamless switching to satellite networks as devices leave cellular coverage regions. This converged offering is designed for customers that require high availability and a failover solution to be assured that critical application data, such as a high value asset’s position, will always be transmitted.
By enabling both cellular and satellite network access from a single eSIM, single management platform, and single radio module, SatPlus uplevels customer experience and drives down hardware and connectivity costs as it reduces operational overhead associated with adding satellite connectivity.
“Businesses around the world have had to contend with interruptions in their operations and services due to limited terrestrial network infrastructure and rollouts. Bringing together satellite and cellular coverage as a network of networks fills in the blank spaces on the terrestrial coverage map and provides an additional layer of connectivity backup. emnify is excited to be the first to commercially offer this enhanced level of truly global connectivity as part of the expanding emnify IoT SuperNetwork,” said Frank Stoecker, CEO and emnify Co-Founder.
“We are excited to accelerate the availability of the industry’s first converged NTN satellite and cellular connectivity offering through our partnership with emnify,” said Tarun Gupta, CPO and Co-Founder, Skylo. “By delivering satellite and cellular connectivity in a single service, we’re helping IoT businesses increase the reliability and reduce the complexity of IoT connectivity, with a single provider, billing plan, and hardware configuration.”
emnify partners up with leading providers of purpose-built hardware
SatPlus is compatible with market-leading, affordable, converged hardware modules from Murata and IoT chipsets from Sony Semiconductor Israel (Sony), conforming with standard form factors and suitable for a variety of device sizes and designs.
“Designed for cellular IoT applications, the ALT1250 is engineered for devices which prioritize battery life, small size, and global coverage. The 4G/5G LPWA chipset supports 2G, CAT-M, NB-IoT and NB NTN connectivity options and is built to meet the needs of IoT device manufacturers looking to provide new levels of uptime and global coverage across business-critical use cases,” said Dima Feldman, VP Product Management and Marketing at Sony Semiconductor Israel. “Our collaboration with emnify, Murata and Skylo takes our vision forward, enabling IoT devices to connect everywhere.”
Module provider Murata is offering the Type 1SC radio module evaluation board including antenna and application development kit compatible with the SuperNetwork SatPlus service.
“The Type 1SC radio module combined with the Sony ALT1250 chipset and the emnify IoT eSIM provides a compact, low cost, CAT-M & NB-IoT module for a new breed of devices that support both cellular and satellite network protocols to provide global coverage for any type of device,” said Hirokazu Nakae, General Manager, Connectivity Module Product Department at Murata.
Customers interested in getting started with SuperNetwork SatPlus can learn more here. SuperNetwork SatPlus will be generally available in June 2024.
Meet emnify at Mobile World Congress, Barcelona
emnify will be at MWC Barcelona, February 26th to 29th. You can find us at the Berlin Mobile booth in Hall 7 Stand 7B81, or in meeting room 7G70MR. To discuss SuperNetwork SatPlus or any other IoT connectivity requirements, book a meeting: https://www.emnify.com/events/mwc-barcelona
About emnify
emnify is the leading cloud building block for cellular communications in the IoT stack, connecting millions of IoT devices globally – from electric vehicles to energy meters, alarm systems to GPS trackers, thermometers to health wearables. The emnify API and SIM technology connect and secure any kind of IoT deployment to its application back-end. emnify’s cloud-native integrations and no-code workflows ensure seamless lifecycle scalability for deployments of all sizes – from local start-up to global enterprise. The award-winning emnify IoT SuperNetwork is the largest globally distributed mobile cloud core network of its kind, supporting local network access (2G – 5G, LTE-M, NB-IoT and satellite) in over 180 countries from more than 25 cloud regions – and counting. emnify’s solution is built on partnerships with the leading hyperscale cloud service providers, system integrators, and hundreds of network operators worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220129205/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom